114 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of benzofuran-3(2H)-one derivatives as novel DRAK2 inhibitors that protect islet?-cells from apoptosis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
East China Normal University
Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
East China Normal University
New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Nebraska Medical Center
Feeling Nature's PAINS: Natural Products, Natural Product Drugs, and Pan Assay Interference Compounds (PAINS).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Monash University (Parkville Campus)
Sequential one-pot synthesis of bis(indolyl)glyoxylamides: Evaluation of antibacterial and anticancer activities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Birla Institute of Technology
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Palack£
Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Merck Research Laboratories
Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Amgen
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Icahn School of Medicine At Mount Sinai
Discovery of a highly potent, orally active mitosis/angiogenesis inhibitor r1530 for the treatment of solid tumors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hoffmann-La Roche
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Oxford
Semi-synthetic aristolactams--inhibitors of CDK2 enzyme.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Schering-Plough Research Institute
Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Boehringer Ingelheim Pharma
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of California
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Oxford
Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
Substituted 3-imidazo[1,2-a]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino-[6,7,1-hi]indol-7-yl)pyrrole-2,5-diones as highly selective and potent inhibitors of glycogen synthase kinase-3.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Ewha Womans University
Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Institute For Biomedical Research
4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Novartis Institutes For Biomedical Research
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Aristotle University of Thessaloniki
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Boehringer Ingelheim Austria
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Cyclacel
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
New potential antitumor compounds from the plant Aristolochia manshuriensis as inhibitors of the CDK2 enzyme.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Schering-Plough Research Institute
Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Leicester
Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Glaxosmithkline
From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Illinois At Chicago
Discovery of 4-(benzylaminomethylene)isoquinoline-1,3-(2H,4H)-diones and 4-[(pyridylmethyl)aminomethylene]isoquinoline-1,3-(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
N-substituted 2'-(aminoaryl)benzothiazoles as kinase inhibitors: hit identification and scaffold hopping.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
4Sc
Search for inhibitors of bacterial and human protein kinases among derivatives of diazepines[1,4] annelated with maleimide and indole cycles.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Institute of General Genetics
Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca Pharmaceuticals
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Leicester
Design, synthesis, and biological evaluation of novel 3-aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as vascular endothelial growth factor receptor (VEGF-R) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eberhard-Karls University
4-(Phenylaminomethylene)isoquinoline-1,3(2H,4H)-diones as potent and selective inhibitors of the cyclin-dependent kinase 4 (CDK4).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
A common protein fold topology shared by flavonoid biosynthetic enzymes and therapeutic targets.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Griffith University
Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Heinrich-Heine-UniversitäT
Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Keimyung University
1-Aryl-4,6-dihydropyrazolo[4,3-d][1]benzazepin-5(1H)-ones: a new class of antiproliferative agents with selectivity for human leukemia and breast cancer cell lines.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Technische UniversitÄT Braunschweig
Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Roche Research Center
Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Wyeth Research
4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Auckland
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Menoufia University
Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Banyu Tsukuba Research Institute
Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
National Institute of Pharmaceutical Education and Research (NIPER)
FLT3 Inhibitors in Acute Myeloid Leukemia: Challenges and Recent Developments in Overcoming Resistance.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Zhengzhou University
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Johnson & Johnson Pharmaceutical Research and Development
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hefei University of Technology
Kinase Inhibitors as Underexplored Antiviral Agents.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Centro De Investigaciones Biol�Gicas Margarita Salas (Csic)
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Csir-Indian Institute of Integrative Medicine
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Louisiana At Lafayette
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The People'S Hospital of Xinjiang Uyghur Autonomous Region
Isolation and biological activity of azocine and azocane alkaloids.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Auckland
Substituted aminobenzimidazole pyrimidines as cyclin-dependent kinase inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bayer Research Center
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Central South University
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
National Institute of Pharmaceutical Education and Research (NIPER)
Development and Therapeutic Potential of NUAKs Inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Science and Technology (Ust)
Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Bristol-Myers Squibb Pharmaceutical Research Institute
Rational Design and Development of Novel CDK9 Inhibitors for the Treatment of Acute Myeloid Leukemia.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Chinese Academy of Sciences
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Southern Medical University
Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Boehringer Ingelheim Pharmaceuticals
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Discovery of potent glycogen synthase kinase 3/cholinesterase inhibitors with neuroprotection as potential therapeutic agent for Alzheimer's disease.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Astrazeneca
Online informatics resources to facilitate cancer target and chemical probe discovery.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Emory University School of Medicine
Structural modifications of indolinones bearing a pyrrole moiety and discovery of a multi-kinase inhibitor with potent antitumor activity.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shenyang Pharmaceutical University
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
The First Affiliated Hospital of Zhengzhou University
CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Lebanese American University
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Eli Lilly
An overview on the synthetic and medicinal perspectives of indenopyrazoles.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Csir-Indian Institute of Chemical Technology
Recent advances in the development of cyclin-dependent kinase 7 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Tianjin University of Science and Technology
A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
China Pharmaceutical University
Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Dundee
Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Padova
Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shenyang Pharmaceutical University
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of South Australia Cancer Research Institute
Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Northeastern University
Discovery of a marine-derived bis-indole alkaloid fascaplysin, as a new class of potent P-glycoprotein inducer and establishment of its structure-activity relationship.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Csir-Indian Institute of Integrative Medicine
Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: synthesis, biological evaluation, and structure-activity relationships.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Daiichi Sankyo
Spongiacidins A-D, new bromopyrrole alkaloids from hymeniacidon sponge ![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Hokkaido University
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Central University of Punjab
Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Jiangnan University
Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Beijing University of Technology
Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Shanghai Haihe Pharmaceutial
Design and synthesis of bis(indolyl)ketohydrazide-hydrazones: Identification of potent and selective novel tubulin inhibitors.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
Birla Institute of Technology
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.![EBI](/images/logo_chembl.png)
![EBI](/images/logo_chembl.png)
University of Chinese Academy of Sciences
A patent review on SARS coronavirus main protease (3CLpro) inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Experimental Drug Development Centre
Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
National Taiwan University
Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
Ankara University
Long residence times revealed by Aurora A kinase-targeting fluorescent probes derived from inhibitors MLN8237 and VX-689.![BDB](/images/logo_bindingdb.png)
![BDB](/images/logo_bindingdb.png)
University of Tartu